| Literature DB >> 30044831 |
Mathilde François1,2, Barbara Clais3, Thierry Blanchon4, Cécile Souty4, Thomas Hanslik1,5, Louise Rossignol4.
Abstract
OBJECTIVE: The aim of this study was to identify factors associated to the duration of symptoms of cystitis. PATIENTS AND METHODS: We conducted a nested survival study using Druti study data. Druti was a cross-sectional survey conducted in adult women visiting a general practitioner in France, for a suspected urinary tract infection between January 2012 and February 2013. For this study, urine cultures were systematically performed for all women. The evolution of symptoms were monitored daily for two weeks. This nested study considered only women with suspected cystitis from Druti; women with pyelonephritis were excluded. To identify independent predictors for duration of symptoms, a Cox proportional hazards regression model was performed.Entities:
Mesh:
Year: 2018 PMID: 30044831 PMCID: PMC6059455 DOI: 10.1371/journal.pone.0201057
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart.
Characteristics of patients with suspected cystitis: Patients followed at two weeks (study population) and patients lost to follow up.
| Patients followed | Patients lost to follow up | ||
|---|---|---|---|
| 46 (18–97) | 42 (18–86) | 0.14 | |
| 415 (94%) | 52 (88%) | 0.08 | |
| 406 (92%) | 51 (86%) | 0.13 | |
| 326 (74%) | 37 (63%) | 0.13 | |
| 113 (26%) | 10 (17%) | 0.21 | |
| 176 (40%) | 31 (53%) | 0.10 | |
| 26 (6%) | 1 (2%) | 0.99 |
* Using Student’s T-test and Chi-Square test
Patients with cystitis with complication risk.
| Factor of complication risk | Number of patients |
|---|---|
| Pregnancy | 8 (2%) |
| Urinary tract anomalies | 18 (4%) |
| Age > 75 years | 32 (7%) |
| Immunocompromising diseases or treatments | 7 (2%) |
Description of the antibiotic prescribed.
| Antibiotic | Dose per tablet | Dosage (number of tablet per day) | Duration of treatment (number of days) | Number of patients treated | |
|---|---|---|---|---|---|
| 2 | 1 (0.2%) | ||||
| 50 | 2 to 3 | 2 to 10j | 7 (2%) | ||
| 100 | 2 | 5 to 6 | 2 (0.5%) | ||
| 2 | 5 to 10 | 8 (2%) | |||
| 3 | 3 | 1 (0.2%) | |||
| 1 | 5 | 3 (0.7%) | |||
| 2 | 4 | 2 (0.5%) | |||
| 3 | 3 to 5 | 3 (0.7%) | |||
| 1 | 5 | 1 (0.2%) | |||
| 2 | 3 | 1 (0.2%) | |||
| 3 | 8 | 1 (0.2%) | |||
| Quinolone | |||||
| Pefloxacin | 800 | 1 | 1 | 6 (1%) | |
| Pipemidic acid | 400 | 1 to 2 | 5 to 10 | 4 (0.9%) | |
| Third generation cephalosporin | |||||
| 200 | 2 | 3 to 4 | 4 (0.9%) | ||
| Cefpodoxime | 100 | 2 | 5 to 10 | 7 (2%) | |
| Ceftriaxone | 1000 | 1 | 1 | 1 (0.2%) | |
| Penicillin | |||||
| Amoxicillin | 1000 | 2 to 3 | 5 to 15 | 12 (3%) | |
| Amoxicillin/clavulanic acid | 1000 | 2 to 3 | 5 to 10 | 6 (1%) | |
| trimethoprim sulfamethoxazole | 400 | 2 to 3 | 5 to 6 | 3 (0.7%) | |
| 800 | 2 | 3 to 8 | 9 (2%) | ||
| 1200 | 1 | 1 | 1 (0.2%) | ||
* Bolt text represent antibiotic guideline-compliant in term of agent used, dose, dosage and duration Urine culture was positive for 326 samples: 275 with E. coli and 61 with MDR isolates.
Factors associated to the duration of symptoms for women with suspected cystitis: Univariate analysis.
| Selected variables | Patients (%) | Median duration of symptoms (days) | Hazards Ratio [95%CI] | ||
|---|---|---|---|---|---|
| Yes | 415 (94.3) | 2 | 0.99 [0,66–1,52] | 0.99 | |
| No | 25 (5.7) | 2 | |||
| Yes | 406 (92.3) | 2 | 1.60 [1,9–2,35] | ||
| No | 34 (7.7) | 3 | |||
| Yes | 326 (74) | 2 | 1.06 [0.85–1.33] | 0.59 | |
| No | 114 (26) | 2 | |||
| Yes | 113 (25.7) | 2 | 1.06 [0.85–1.32] | 0.61 | |
| No | 326 (74.3) | 2 | |||
| Yes | 176 (40) | 2 | 0.83 [0.68–1.02] | 0.07 | |
| No | 263 (60) | 2 | |||
| Yes | 413 (64) | 1.5 | 1.30 [0.86–1.95] | 0.22 | |
| No | 26 (6) | 2 | |||
| Yes | 62 (14.1) | 3 | 0.71 [0.53–0.95] | ||
| No | 377 (85.9) | 2 | |||
| Yes | 145 (33) | 3 | 0.71 [0.57–0.87] | ||
| No | 295 (67) | 2 | |||
| Yes | 375 (85) | 3 | 0.85 [0.65–1.12] | 0.25 | |
| No | 65 (15) | 2 | |||
| Yes | 34 (7.7) | 3 | 0.87 [0.61–1.24] | 0.45 | |
| No | 405 (92.3) | 2 | |||
| Yes | 349 (79.3) | 2 | 1.07 [0.84–1.35] | 0.61 | |
| No | 91 (20.7) | 2 | |||
| Yes | 48 (10.9) | 2 | 1.04 [0.76–1.42] | 0.83 | |
| No | 392 (89.1) | 2 | |||
| Yes | 295 (67) | 2 | 0.83 [0.67–1.01] | 0.07 | |
| No | 145 (33) | 2 | |||
| Yes | 70 (15.9) | 3 | 0.81 [0.62–1.05] | 0.11 | |
| No | 370 (84.1) | 2 | |||
| Yes | 401 (91.6) | 2 | 0.77 [0.55–1.10] | 0.15 | |
| No | 37 (8.4) | 2 | |||
| Yes | 423 (96.8) | 2 | 0.60 [0.35–1.03] | ||
| No | 14 (3.2) | 2 | |||
| Yes | 326 (74.1) | 2 | 1.00 [0.80–1.25] | 0.99 | |
| No | 114 (25.9) | 2 | |||
| Yes | 275 (62.5) | 2 | 0.92 [0.75–1.12] | 0.40 | |
| No | 165 (37.5) | 2 | |||
| Yes | 61 (13.9) | 3 | 0.88 [0.66–1.17] | 0.38 | |
| No | 379 (86.1) | 2 | |||
| Yes | 424 (96.4) | 3 | 0,71 [0.16–1.26] | 0.37 | |
| No | 16 (3.6) | 2 | |||
| Yes | 248 (56.5) | 2 | 1.30 [1.06–1.58] | ||
| No | 176 (41.5) | 3 | |||
| Yes | 347 (81%) | 2 | 1.07 [0.82–1.40] | 0.61 | |
| No | 83 (19%) | 2 |
a since the inclusion consultation
bUnivariate cox models
c Cystitis with complication risk was defined as cystitis occuring in a woman with urinary tract anomalies, or severe renal failure, or immunocompromising disease/treatment, or pregnancy, or aged 75 years and older or over 65 years old with criteron of fragility;
d UTI: Urinary tract infection
e Patients with ≥ four UTIs/year
f MDR: multidrug resistance defined as acquired resistance to at least three of antimicobial antibiotics according to the natural resistance of the isolate.
Factors associated to the duration of symptoms for women with suspected cystitis: Multivariate analysis.
| Hazards Ratio | ||
|---|---|---|
| 0.68 [0.55–0.85] | ||
| 1.70 [1.15–2.52] | ||
| 0.52 [0.30–0.90] |